# A SAD Study of ZT002 Injection in Healthy Participants

> **NCT06423872** · PHASE1 · COMPLETED · sponsor: **Beijing QL Biopharmaceutical Co.,Ltd** · enrollment: 28 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ZT002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06423872
- **Lead sponsor:** Beijing QL Biopharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-19
- **Primary completion:** 2023-10-20
- **Final completion:** 2023-12-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423872, "A SAD Study of ZT002 Injection in Healthy Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06423872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*